Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)

Mikkael A. Sekeres, Justin Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Patricia Font Lopez, Joshua F. Zeidner, Maria Diez Campelo, Carlos Graux, Jane Liesveld, Dominik Selleslag, Nikolay Tzvetkov, Robert J. Fram, Dan Zhao, Jill Bell, Sharon Friedlander, Douglas V. Faller, Lionel Adès

Research output: Contribution to journalComment/debatepeer-review

Abstract

In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azacitidine alone arm. Instead of n=30 and n=29 as originally published, these have now been corrected to n=29 for pevonedistat + azacitidine and n=30 for azacitidine. No changes were required to the response rate percentages as these were calculated using the correct denominators. The updated files are attached to this correction.

Original languageEnglish (US)
Pages (from-to)3637
Number of pages1
JournalLeukemia
Volume35
Issue number12
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML (Leukemia, (2021), 35, 7, (2119-2124), 10.1038/s41375-021-01125-4)'. Together they form a unique fingerprint.

Cite this